M&ABusinessLine
Piramal Pharma to acquire remaining 26% stake in Yapan Bio
Positive+33
GreyOak summary
Piramal Pharma Limited announced it will acquire the remaining 26% equity stake in Yapan Bio Private Limited via an exercised call option. This transaction will increase Piramal's shareholding from 74% to 100%, making Yapan a wholly owned subsidiary. Final terms, including consideration and the effective transfer date, are yet to be finalized.
What it affects
- Piramal PharmaPPLPHARMAPositive +33
Acquiring remaining 26% stake in Yapan Bio.Rolling sentiment Positive +21
Source
Read the original at BusinessLineMore Piramal Pharma news
No other recent stories about Piramal Pharma.
All Piramal Pharma news →